Sertoli Technologies

Sertoli Technologies is a biotechnology company focused on developing cell-based therapies that leverage the unique immunomodulatory properties of Sertoli cells. The company's primary mission is to create an immunoprivileged environment for transplanted cells, specifically targeting the treatment of Type 1 Diabetes. By co-transplanting Sertoli cells with insulin-producing islet cells, the technology aims to protect the graft from immune rejection without the need for chronic systemic immunosuppression. This approach utilizes the natural 'nurse cell' functions of Sertoli cells, which provide both physical and chemical protection to developing germ cells. Sertoli Technologies is currently in the pre-clinical stage, refining its platform for broader applications in regenerative medicine and transplantation.